Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

AC Immune S.A. (ACIU)

AC Immune S.A. (ACIU)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 474,285
  • Shares Outstanding, K 67,562
  • Annual Sales, $ 111,750 K
  • Annual Income, $ 45,740 K
  • 60-Month Beta 0.49
  • Price/Sales 3.95
  • Price/Cash Flow 9.88
  • Price/Book 1.72

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/20
See More
  • Average Estimate -0.28
  • Number of Estimates 2
  • High Estimate -0.28
  • Low Estimate -0.28
  • Prior Year -0.23
  • Growth Rate Est. (year over year) -21.74%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.52 +7.67%
on 07/31/20
13.00 -46.00%
on 07/16/20
-0.04 (-0.57%)
since 07/02/20
3-Month
6.52 +7.67%
on 07/31/20
13.00 -46.00%
on 07/16/20
+0.20 (+2.93%)
since 05/01/20
52-Week
4.07 +72.48%
on 03/18/20
13.00 -46.00%
on 07/16/20
+1.42 (+25.36%)
since 08/02/19

Most Recent Stories

More News
AC Immune to Present Advances in Two of the Company's World Leading Programs at the Upcoming Alzheimer's Association International Conference

AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company, with a broad pipeline focused on neurodegenerative diseases, today announced two oral presentations will be delivered...

ACIU : 7.02 (+7.50%)
AC Immune Advances Alzheimer's Vaccine to Phase Ib/IIa Study

AC Immune (ACIU) advances its Alzheimer's disease vaccine, ACI-35.030, to phase Ib/IIa study.

JNJ : 147.35 (+1.09%)
RHHBY : 44.1600 (+2.46%)
EBS : 118.00 (+6.08%)
ACIU : 7.02 (+7.50%)
Tau-PET Tracer PI-2620 Could Set New Standards for an Improved Diagnosis of Progressive Supranuclear Palsy

Life Molecular Imaging and AC Immune SA (NASDAQ: ACIU) announce the publication of clinical data of the investigational Tau-positron emission tomography (PET) tracer PI-2620 in patients with progressive...

ACIU : 7.02 (+7.50%)
AC Immune Announces Results of Annual General Meeting

AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, announced AC Immune shareholders approved all of the resolutions...

ACIU : 7.02 (+7.50%)
AC Immune CEO to Showcase Novel Target Programs at UBS Global Healthcare Conference

AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced that it will showcase key programs focused...

ACIU : 7.02 (+7.50%)
AC Immune (ACIU) Reports Q1 Loss, Tops Revenue Estimates

AC Immune (ACIU) delivered earnings and revenue surprises of 47.06% and 24.54%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

ACIU : 7.02 (+7.50%)
AC Immune Reports Q1 2020 Financial Results and Provides Business Update

AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced financial results for the first quarter...

ACIU : 7.02 (+7.50%)
AC Immune Reports Full-Year 2019 Financial Results and Provides 2020 R&D Outlook

EQNX::TICKER_START (NasdaqGM:ACIU), EQNX::TICKER_END

ACIU : 7.02 (+7.50%)
Company News for Mar 24, 2020

Companies in the news are: HAS, PCG, WTRH, ACIU

PCG : 9.10 (-2.67%)
HAS : 74.87 (+2.90%)
ACIU : 7.02 (+7.50%)
WTRH : 5.43 (+1.69%)
Internationally Renowned Neurologist Dr. Juan Fortea Joins AC Immune's Clinical Advisory Board

AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced Dr. Juan Fortea, an internationally renowned...

ACIU : 7.02 (+7.50%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Sell with a Weakest short term outlook on maintaining the current direction.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Trade ACIU with:

Business Summary

AC Immune SA is a biopharmaceutical company. It develops, discover and design novel, proprietary medicines for prevention, diagnosis and treatment of neurodegenerative diseases. The Company's pipeline includes Crenezumab, ACI-24, Anti-Tau antibody, Morphomer Tau, Tau-PET imaging agent, Morphomer Abeta...

See More

Key Turning Points

2nd Resistance Point 7.41
1st Resistance Point 7.21
Last Price 7.02
1st Support Level 6.71
2nd Support Level 6.41

See More

52-Week High 13.00
Fibonacci 61.8% 9.59
Fibonacci 50% 8.53
Fibonacci 38.2% 7.48
Last Price 7.02
52-Week Low 4.07

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar